MX2021002742A - Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc. - Google Patents
Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc.Info
- Publication number
- MX2021002742A MX2021002742A MX2021002742A MX2021002742A MX2021002742A MX 2021002742 A MX2021002742 A MX 2021002742A MX 2021002742 A MX2021002742 A MX 2021002742A MX 2021002742 A MX2021002742 A MX 2021002742A MX 2021002742 A MX2021002742 A MX 2021002742A
- Authority
- MX
- Mexico
- Prior art keywords
- phosphoinositide
- pharmaceutically acceptable
- combination therapy
- kinase inhibitor
- binding moiety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención proporciona un método para tratar el cáncer en un sujeto que lo necesita, que comprende administrar al sujeto: (a) un compuesto de Fórmula I: (ver formula I) o una sal farmacéuticamente aceptable de este, en donde R es hidrógeno o un grupo acilo; y (b) un inhibidor de la señalización de PD-1; en donde el compuesto de Fórmula I o una sal farmacéuticamente aceptable de este y el inhibidor de la señalización de PD-1 se administran en cantidades que en combinación son terapéuticamente efectivos. La invención proporciona además una composición farmacéutica que comprende un compuesto de Fórmula I o una sal farmacéuticamente aceptable de este, un inhibidor de la señalización de PD-1 y un portador o excipiente farmacéuticamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862729648P | 2018-09-11 | 2018-09-11 | |
PCT/US2019/050373 WO2020055840A1 (en) | 2018-09-11 | 2019-09-10 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002742A true MX2021002742A (es) | 2021-08-11 |
Family
ID=69721106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002742A MX2021002742A (es) | 2018-09-11 | 2019-09-10 | Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc. |
Country Status (15)
Country | Link |
---|---|
US (2) | US11234986B2 (es) |
EP (1) | EP3849554A4 (es) |
JP (1) | JP7467423B2 (es) |
KR (1) | KR20210087438A (es) |
CN (1) | CN113164466A (es) |
AU (1) | AU2019340376A1 (es) |
BR (1) | BR112021004371A2 (es) |
CA (1) | CA3112177A1 (es) |
EA (1) | EA202190748A1 (es) |
IL (1) | IL281303A (es) |
MA (1) | MA53619A (es) |
MX (1) | MX2021002742A (es) |
PH (1) | PH12021550471A1 (es) |
SG (1) | SG11202102343QA (es) |
WO (1) | WO2020055840A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112778212B (zh) * | 2021-01-28 | 2022-03-15 | 苏州莱克施德药业有限公司 | 库潘尼西中间体2-胺基嘧啶-5-羧酸甲酯的合成方法 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
CA2407593C (en) | 2000-04-27 | 2011-01-11 | Yamanouchi Pharmaceutical Co. Ltd. | Fused heteroaryl derivatives |
DE60321548D1 (de) | 2002-03-13 | 2008-07-24 | Janssen Pharmaceutica Nv | Carbonylamino- derivativate als neue inhibitoren von histone deacetylase |
KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
EP1485099B1 (en) | 2002-03-13 | 2010-07-07 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
AU2003218738B2 (en) | 2002-03-13 | 2009-01-08 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
WO2004067535A1 (ja) | 2003-01-29 | 2004-08-12 | Takeda Pharmaceutical Company Limited | チエノピリミジン化合物およびその用途 |
AU2005230682B2 (en) | 2004-04-05 | 2010-10-21 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
JP4862654B2 (ja) | 2004-10-08 | 2012-01-25 | アステラス製薬株式会社 | 芳香環縮合ピリミジン誘導体 |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
EP1855760A2 (en) | 2005-02-03 | 2007-11-21 | TopoTarget UK Limited | Combination therapies using hdac inhibitors |
US7834011B2 (en) | 2006-01-19 | 2010-11-16 | Janssen Pharmaceutica N.V. | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
US8114876B2 (en) | 2006-01-19 | 2012-02-14 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
WO2007082880A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
MX2008013583A (es) | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
TWI409268B (zh) | 2006-04-26 | 2013-09-21 | Hoffmann La Roche | 醫藥化合物 |
EP2402347A1 (en) | 2006-04-26 | 2012-01-04 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
EP2018366A4 (en) | 2006-05-16 | 2010-08-04 | Univ Mcgill | HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR |
WO2008033747A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
JP5580592B2 (ja) | 2006-09-11 | 2014-08-27 | キュリス,インコーポレイテッド | 亜鉛結合部分を含むキナゾリン系egfrインヒビター |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
US20080161320A1 (en) | 2006-09-11 | 2008-07-03 | Xiong Cai | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
AU2007296740B2 (en) | 2006-09-11 | 2012-09-27 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
KR101433629B1 (ko) | 2006-09-11 | 2014-08-27 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 티로신 키나아제 억제제 |
US8399452B2 (en) | 2006-10-28 | 2013-03-19 | Methylgene Inc. | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors |
US9487533B2 (en) | 2006-12-07 | 2016-11-08 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
EP2114949A1 (en) | 2006-12-07 | 2009-11-11 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
PE20090519A1 (es) | 2007-02-15 | 2009-05-29 | Novartis Ag | Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida |
JP2010522163A (ja) | 2007-03-20 | 2010-07-01 | キュリス,インコーポレイテッド | 亜鉛結合部位を含むRafキナーゼインヒビター |
WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
PE20090678A1 (es) | 2007-09-12 | 2009-06-27 | Genentech Inc | Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso |
WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
WO2009058895A1 (en) | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
JP2011525535A (ja) | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | PI3K/mTOR阻害剤 |
WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
SG196815A1 (en) | 2009-01-08 | 2014-02-13 | Curis Inc | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
EP3192811A1 (en) * | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
WO2010105008A2 (en) | 2009-03-12 | 2010-09-16 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
AU2010314287A1 (en) | 2009-10-12 | 2012-05-03 | F. Hoffmann-La Roche Ag | Combinations of a PI3K inhibitor and a MEK inhibitor |
WO2011130628A1 (en) | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
AU2012236367B2 (en) | 2011-04-01 | 2014-10-09 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
ES2708669T3 (es) | 2011-08-01 | 2019-04-10 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK |
ES2953441T3 (es) * | 2015-06-25 | 2023-11-13 | Immunomedics Inc | Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer |
EP3474856B1 (en) * | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
JP7189870B2 (ja) | 2016-10-20 | 2022-12-14 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Vista及びpd-1経路の二重阻害剤 |
MA46728A (fr) * | 2016-11-02 | 2019-09-11 | Curis Inc | Polythérapie avec un inhibiteur de phosphoinositide 3-kinase avec une fraction de liaison au zinc |
-
2019
- 2019-09-10 SG SG11202102343QA patent/SG11202102343QA/en unknown
- 2019-09-10 US US16/565,921 patent/US11234986B2/en active Active
- 2019-09-10 CA CA3112177A patent/CA3112177A1/en active Pending
- 2019-09-10 CN CN201980074099.0A patent/CN113164466A/zh active Pending
- 2019-09-10 MA MA053619A patent/MA53619A/fr unknown
- 2019-09-10 AU AU2019340376A patent/AU2019340376A1/en active Pending
- 2019-09-10 MX MX2021002742A patent/MX2021002742A/es unknown
- 2019-09-10 JP JP2021513198A patent/JP7467423B2/ja active Active
- 2019-09-10 BR BR112021004371-3A patent/BR112021004371A2/pt unknown
- 2019-09-10 KR KR1020217010381A patent/KR20210087438A/ko unknown
- 2019-09-10 WO PCT/US2019/050373 patent/WO2020055840A1/en active Application Filing
- 2019-09-10 EA EA202190748A patent/EA202190748A1/ru unknown
- 2019-09-10 EP EP19860430.8A patent/EP3849554A4/en active Pending
-
2021
- 2021-03-05 PH PH12021550471A patent/PH12021550471A1/en unknown
- 2021-03-07 IL IL281303A patent/IL281303A/en unknown
- 2021-12-21 US US17/557,567 patent/US20220249502A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020055840A1 (en) | 2020-03-19 |
EP3849554A4 (en) | 2022-06-01 |
AU2019340376A1 (en) | 2021-04-08 |
US20220249502A1 (en) | 2022-08-11 |
KR20210087438A (ko) | 2021-07-12 |
JP7467423B2 (ja) | 2024-04-15 |
SG11202102343QA (en) | 2021-04-29 |
CN113164466A (zh) | 2021-07-23 |
MA53619A (fr) | 2021-12-15 |
US11234986B2 (en) | 2022-02-01 |
EP3849554A1 (en) | 2021-07-21 |
JP2022500374A (ja) | 2022-01-04 |
US20200078364A1 (en) | 2020-03-12 |
EA202190748A1 (ru) | 2021-07-22 |
CA3112177A1 (en) | 2020-03-19 |
IL281303A (en) | 2021-04-29 |
BR112021004371A2 (pt) | 2021-05-25 |
PH12021550471A1 (en) | 2021-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
MY196455A (en) | Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection | |
CR20220363A (es) | Compuestos tricíclicos sustituidos | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
CR20220312A (es) | Compuestos tricíclicos sustituidos | |
PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
CR20230310A (es) | Inhibidores de prmt5 | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
PH12019500858A1 (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
PH12020551494A1 (en) | Substituted imidazolidin-2-one derivatives as prmt5 inhibitors | |
MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. |